Case-Based Learning on ICU-Acquired Weakness and Progressive Functional Rehabilitation

Abstract

ICU-acquired weakness (ICU-AW) is a prevalent neuromuscular complication among critically ill patients, often resulting in prolonged functional impairment and increased healthcare burden. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical presentation, diagnostic strategies, and management of ICU-AW, with a special emphasis on case-based learning and progressive functional rehabilitation. The discussion integrates recent advances, guideline recommendations, and practical implications for intensivists and rehabilitation specialists, aiming to enhance patient outcomes through early recognition and tailored therapeutic strategies.

Introduction

Intensive care unit-acquired weakness (ICU-AW) encompasses a spectrum of neuromuscular disorders acquired during critical illness and mechanical ventilation. Characterized by diffuse, symmetric limb weakness and diminished respiratory muscle strength, ICU-AW significantly impacts morbidity, prolonged hospitalization, and long-term disability. As survival rates from critical illness improve, the focus has shifted toward optimizing functional recovery and quality of life, highlighting the need for evidence-based rehabilitation protocols. This review utilizes a case-based approach to illustrate key aspects of pathophysiology, risk stratification, clinical assessment, and the integration of progressive rehabilitation strategies for ICU-AW.

Epidemiology / Disease Burden

ICU-AW affects up to 40-60% of patients requiring mechanical ventilation for more than one week, with the incidence rising in those with sepsis, multi-organ failure, or prolonged immobility. The disease burden is substantial, manifesting as persistent physical disability, delayed weaning, and increased mortality. Recent multicenter studies and registries, such as the EPIC II and SPRINT-SARI, underscore the global prevalence and the growing need for standardized assessment and rehabilitation protocols. The socioeconomic impact is profound, with increased resource utilization, readmissions, and long-term care requirements, underscoring the importance of early detection and intervention.

Pathophysiology

The pathophysiology of ICU-AW is multifactorial, involving critical illness polyneuropathy (CIP), critical illness myopathy (CIM), or a combination of both. Contributing mechanisms include systemic inflammatory response, microvascular dysfunction, mitochondrial injury, impaired protein synthesis, and neurotoxic effects of medications such as corticosteroids and neuromuscular blockers. Prolonged immobilization exacerbates muscle atrophy via upregulation of proteolytic pathways, including the ubiquitin-proteasome and autophagy-lysosome systems. Disruption of neuromuscular transmission and bioenergetic failure further compromise muscle function, while persistent catabolism impairs recovery even after resolution of the acute illness.

Risk Factors

Major risk factors for ICU-AW include sepsis, systemic inflammatory response syndrome, multi-organ failure, hyperglycemia, prolonged mechanical ventilation, immobility, and exposure to specific medications such as corticosteroids and neuromuscular blocking agents. Advanced age, pre-existing comorbidities (e.g., diabetes, chronic kidney disease), and severity of illness scores (APACHE II, SOFA) are also predictive. Early identification of at-risk patients is crucial for implementing preventive measures such as glycemic control, judicious sedation, and early mobilization protocols.

Clinical Features

Patients typically present with symmetric, flaccid limb weakness involving proximal and distal muscles, while facial muscles are spared. Deep tendon reflexes are often reduced or absent, and sensory loss is variable, more prominent in CIP. Respiratory muscle involvement leads to difficulty in weaning from mechanical ventilation and increased risk of pulmonary complications. The clinical course is insidious, with weakness often recognized only upon sedation interruption or initiation of mobilization. Functional impairments persist after ICU discharge, manifesting as delayed ambulation, impaired activities of daily living, and reduced quality of life.

Diagnosis

Diagnosis is primarily clinical, based on the Medical Research Council (MRC) sum score, with a score less than 48 indicative of significant weakness. Electrophysiological studies help differentiate between CIP and CIM; nerve conduction studies reveal reduced amplitude in CIP, while electromyography shows myopathic changes in CIM. Muscle and nerve biopsies are reserved for atypical or refractory cases. Recent advances include the use of ultrasound for muscle thickness assessment and bioimpedance analysis for muscle quality, providing bedside tools for monitoring muscle mass and guiding rehabilitation.

Treatment & Management

The cornerstone of ICU-AW management is prevention and supportive care. Early mobilization, even during mechanical ventilation, has been shown to reduce the incidence and severity of ICU-AW. Protocolized sedation interruption, glycemic control, avoidance of unnecessary corticosteroids and neuromuscular blockade, and optimization of nutrition support are evidence-based strategies. Progressive functional rehabilitation, tailored to patient tolerance and clinical status, is essential for restoring muscle strength and function. Interdisciplinary teams comprising physiatrists, physical therapists, occupational therapists, and critical care physicians are vital for individualized care plans and goal setting.

Recent Advances / Emerging Therapies

Recent research highlights the efficacy of early and intensive physical therapy interventions, including in-bed cycling and neuromuscular electrical stimulation, in mitigating muscle atrophy and improving outcomes. Pharmacological agents targeting muscle anabolism, such as selective androgen receptor modulators, are under investigation. Biomarkers for muscle injury and regeneration, as well as advanced imaging modalities, offer promise for early detection and monitoring of ICU-AW progression. Tele-rehabilitation and technology-assisted functional assessment are emerging to support long-term recovery post-discharge.

Guideline Recommendations

International guidelines from the Society of Critical Care Medicine and European Society of Intensive Care Medicine recommend routine screening for ICU-AW using standardized bedside tools, implementation of early mobilization protocols, and minimization of sedative and neuromuscular blocking agent use. Individualized rehabilitation, nutritional optimization, and glycemic control are endorsed. Ongoing research is needed to refine rehabilitation dosing, timing, and integration with pharmacological therapies for optimal patient-centered outcomes.

Conclusion

ICU-acquired weakness remains a significant challenge in critical care, with multidimensional impacts on patient recovery and healthcare systems. Case-based learning facilitates deeper understanding of the complex interplay between pathophysiology, risk factors, and practical management strategies. Early recognition, prevention, and progressive functional rehabilitation are paramount for improving patient outcomes. Multidisciplinary collaboration, adherence to guideline-based protocols, and ongoing research into novel therapies will continue to advance the care and rehabilitation of ICU survivors with acquired weakness.